FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026
FocalTherics reported preliminary Q2 revenue of $12.7 million to $13.2 million for its continuing HIFU operations, reflecting 34% to 39% year-over-year growth. Gross margins are expected between 54% and 56%, up 3% to 5% from the prior year, while the company shifts strategy by classifying its ESWL and Distribution segments as discontinued operations.
Key figures
- Revenue
- $12.7 - $13.2 million
- Revenue Yoy
- 34% - 39%
- Gross margin
- 54% - 56%
- Cash and equivalents
- $21.5 million
- Gross margin yoy growth
- 3% - 5%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.